Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Sipuleucel-T + Testosterone cypionate |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Sipuleucel-T | Provenge | APC 8015 | Provenge (sipuleucel-T) is composed of autologous dendritic cells exposed to a PAP-GCSF fusion protein (PA2024), which stimulates a cytotoxic immune response towards PAP-expressing tumor cells (PMID: 25565923, PMID: 25708576). Provenge (sipuleucel-T) is FDA-approved for use in patients with metastatic castration-resistant prostate cancer (FDA.gov). | |
| Testosterone cypionate | Depo-Testosterone | Depotest|Depovirin|Pertestis | Testosterone cypionate is made up of an eight carbon ester form, whcih inhibits the secretion of gonadotropin and blocks the generation of estrogen (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06100705 | Phase II | Sipuleucel-T + Testosterone cypionate | Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC | Recruiting | USA | 0 |